Prognostic significance of pretreatment 18F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma.
Sung, AJ; Weiss, BD; Sharp, SE; Zhang, B; Trout, AT.
Pediatric Radiology.
2021;
51:1400-1405.
Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
Granger, MM; Naranjo, A; Bagatell, R; DuBois, SG; McCune, JS; Tenney, SC; Weiss, BD; Mosse, YP; Asgharzadeh, S; Grupp, SA; et al.
Transplantation and cellular therapy.
2021;
27:490.e1-490.e8.
Metastatic neuroblastoma masquerading as infantile hemangioma in a 4-month-old child.
Karkoska, K; Ricci, K; VandenHeuvel, K; Trout, AT; Smith, EA; Kotagal, M; Weiss, B.
Pediatric Blood and Cancer.
2021;
68.
Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
Emberesh, M; Rubinstein, JD; Young, J; Benoit, SW; Dandoy, CE; Weiss, BD.
Pediatric Blood and Cancer.
2021;
68.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss, BD; Wolters, PL; Plotkin, SR; Widemann, BC; Tonsgard, JH; Blakeley, J; Allen, JC; Schorry, E; Korf, B; Robison, NJ; et al.
Journal of Clinical Oncology.
2021;
39:797-806.
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross, AM; Wolters, PL; Dombi, E; Baldwin, A; Whitcomb, P; Fisher, MJ; Weiss, B; Kim, A; Bornhorst, M; Shah, AC; et al.
New England Journal of Medicine.
2020;
382:1430-1442.
Sentinel lymph node biopsy in head and neck rhabdomyosarcoma.
Turpin, B; Pressey, JG; Nagarajan, R; Weiss, BD; Trout, AT; Gelfand, MJ; Pater, L; Vatner, RE; Breneman, JC; Dasgupta, R.
Pediatric Blood and Cancer.
2019;
66.
Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.
DuBois, SG; Mosse, YP; Fox, E; Kudgus, RA; Reid, JM; McGovern, R; Groshen, S; Bagatell, R; Maris, JM; Twist, CJ; et al.
Clinical Cancer Research.
2018;
24:6142-6149.
NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.
Weiss, B; Plotkin, S; Widemann, B; Tonsgard, J; Blakeley, J; Allen, J; Schorry, E; Korf, B; Rosser, T; Goldman, S; et al.
Neuro-Oncology.
2018;
20:i143-i143.